How tezepelumab ranks in severe asthma subset with low eosinophils: Data Byte

Full data released Friday from the Phase III NAVIGATOR trial suggest tezepelumab is effective in severe asthma patients regardless of eosinophil count, but statistical significance remains to be shown.

Detailed data showed the TSLP inhibitor from partners  AstraZeneca plc (LSE:AZN; NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) reduced the annualized asthma exacerbation rate (AAER) by 56% in severe asthma patients vs. placebo (p<0.001), which is slightly better than approved mAb therapies for the same population. ...